-
1
-
-
33750337141
-
-
Available at
-
Avastin Drug Warning. 2005. Available at: http://www.fda. gov/medwatch/SAFETY/2005/Avastin-dearhcp.pdf
-
(2005)
Avastin Drug Warning
-
-
-
2
-
-
33646440660
-
Testing intravitreal toxicity of bevacizumab (Avastin)
-
Manzano RP, Peyman GA, Khan P, et al. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006;26:257-261.
-
(2006)
Retina
, vol.26
, pp. 257-261
-
-
Manzano, R.P.1
Peyman, G.A.2
Khan, P.3
-
3
-
-
34247182509
-
Bevacizumab for neovascular ocular diseases
-
Review
-
Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother. 2007;41:614-625. Review.
-
(2007)
Ann Pharmacother
, vol.41
, pp. 614-625
-
-
Lynch, S.S.1
Cheng, C.M.2
-
4
-
-
33750296920
-
The international intrav-itreal bevacizumab safety study: Using the internet to assess drug safety worldwide
-
Fung AE, Rosenfeld PJ, Reichel E. The international intrav-itreal bevacizumab safety study: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344-1349.
-
(2006)
Br J Ophthalmol
, vol.90
, pp. 1344-1349
-
-
Fung, A.E.1
Rosenfeld, P.J.2
Reichel, E.3
-
5
-
-
0033856243
-
Expression of vascular en-dothelial growth factor and its receptors in inflamed and vascu-larized human corneas
-
Philipp W, Speicher L, Humpel C. Expression of vascular en-dothelial growth factor and its receptors in inflamed and vascu-larized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514-2522.
-
(2000)
Invest Ophthalmol Vis Sci
, vol.41
, pp. 2514-2522
-
-
Philipp, W.1
Speicher, L.2
Humpel, C.3
-
6
-
-
34247519047
-
Inhibition of experimental corneal neovascularization by bevacizumab (Avastin)
-
Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalmol. 2007;91:804-807.
-
(2007)
Br J Ophthalmol
, vol.91
, pp. 804-807
-
-
Manzano, R.P.1
Peyman, G.A.2
Khan, P.3
-
7
-
-
34250315760
-
Topical bevacizumab therapy for corneal neovascularization
-
DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol. 2007;125:834-836.
-
(2007)
Arch Ophthalmol
, vol.125
, pp. 834-836
-
-
DeStafeno, J.J.1
Kim, T.2
-
8
-
-
34548722080
-
Subconjunctival bevacizumab for corneal neovascularization
-
Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2007;245:1577-1579.
-
(2007)
Graefes Arch Clin Exp Ophthalmol
, vol.245
, pp. 1577-1579
-
-
Erdurmus, M.1
Totan, Y.2
-
9
-
-
0031911115
-
Increased levels of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma
-
Tripathi RC, Li J, Tripathi BJ, et al. Increased levels of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998;105:232-237.
-
(1998)
Ophthalmology
, vol.105
, pp. 232-237
-
-
Tripathi, R.C.1
Li, J.2
Tripathi, B.J.3
-
10
-
-
33745392312
-
Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy
-
Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142:155-158.
-
(2006)
Am J Ophthalmol
, vol.142
, pp. 155-158
-
-
Oshima, Y.1
Sakaguchi, H.2
Gomi, F.3
Tano, Y.4
-
11
-
-
33745413422
-
Intracameral bevacizumab for iris rubeosis
-
Grisanti S, Biester S, Peters S, et al. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol. 2006;142:158-160.
-
(2006)
Am J Ophthalmol
, vol.142
, pp. 158-160
-
-
Grisanti, S.1
Biester, S.2
Peters, S.3
-
14
-
-
0033847918
-
Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity
-
Lashkari K, Hirose T, Yazdani J, et al. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol. 2000;156:1337-1344.
-
(2000)
Am J Pathol
, vol.156
, pp. 1337-1344
-
-
Lashkari, K.1
Hirose, T.2
Yazdani, J.3
-
15
-
-
67749132246
-
Bevacizumab for salvage treatment in threshold retinopathy of prematurity
-
Jan/Feb
-
Lalwani GA, Buch M, Cardone S, et al. Bevacizumab for salvage treatment in threshold retinopathy of prematurity. Retinal Physician. 2007; Jan/Feb: 77-78.
-
(2007)
Retinal Physician
, pp. 77-78
-
-
Lalwani, G.A.1
Buch, M.2
Cardone, S.3
-
16
-
-
34250766682
-
Intravitreal beva-cizumab in aggressive posterior retinopathy of prematurity
-
Travassos A, Teixeira S, Ferreira P, et al. Intravitreal beva-cizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging. 2007;38:233-237.
-
(2007)
Ophthalmic Surg Lasers Imaging
, vol.38
, pp. 233-237
-
-
Travassos, A.1
Teixeira, S.2
Ferreira, P.3
-
17
-
-
0027942607
-
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopa-thy and other retinal disorders
-
Aiello LP, Avery RL, Arrigg PG, et. Al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopa-thy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
-
(1994)
N Engl J Med
, vol.331
, pp. 1480-1487
-
-
Aiello, L.P.1
Avery, R.L.2
Arrigg, P.G.3
et., Al.4
-
18
-
-
0019473351
-
Photocoag-ulation treatment of proliferative diabetic retinopathy: Clinical application of Diabetic Retinopathy Study (DRS), DRS
-
The Diabetic Retinopathy Study Research Group
-
The Diabetic Retinopathy Study Research Group. Photocoag-ulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS), DRS Report Number 8. Ophthalmology. 1981;88:583-600.
-
(1981)
Ophthalmology
, vol.88
, pp. 583-600
-
-
-
19
-
-
33646464279
-
Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by virtre-ous hemorrhage
-
Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by virtre-ous hemorrhage. Retina. 2006;26:275-278.
-
(2006)
Retina
, vol.26
, pp. 275-278
-
-
Spaide, R.F.1
Fisher, Y.L.2
-
20
-
-
33747335983
-
Use of intravitreal bevacizumab as a preoper-ative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy
-
Chen E, Park C. Use of intravitreal bevacizumab as a preoper-ative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. 2006;26:699-670.
-
(2006)
Retina
, vol.26
, pp. 699-670
-
-
Chen, E.1
Park, C.2
-
21
-
-
33748982649
-
Intravitreal beva-cizumab (Avastin) in the treatment of proliferative diabetic retinopathy
-
Avery RL, Pearlman J, Pieramici DL, et al. Intravitreal beva-cizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695-1705.
-
(2006)
Ophthalmology
, vol.113
, pp. 1695-1705
-
-
Avery, R.L.1
Pearlman, J.2
Pieramici, D.L.3
-
22
-
-
67749113954
-
Panretinal photocoag-ulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study)
-
Nov epub ahead of print
-
Tonello M, Costa RA, Almeida FPP, et al. Panretinal photocoag-ulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol Scand. 2007 Nov (epub ahead of print).
-
(2007)
Acta Ophthalmol Scand
-
-
Tonello, M.1
Costa, R.A.2
Almeida, F.P.P.3
-
23
-
-
0022347471
-
Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Group
-
Early Treatment Diabetic Retinopathy Study Research Group
-
Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Group Report Number 1. Arch Ophthalmol. 1985;103:1796-1806.
-
(1985)
Arch Ophthalmol
, vol.103
, pp. 1796-1806
-
-
-
24
-
-
38349162286
-
Intravitreal triam-cinolone versus bevacizumab for refractory diabetic mac-ular oedema (IBEME study)
-
Paccola L, Costa RA, Folgosa MS, et al. Intravitreal triam-cinolone versus bevacizumab for refractory diabetic mac-ular oedema (IBEME study). Br J Ophthalmol. 2008;92:76-80.
-
(2008)
Br J Ophthalmol
, vol.92
, pp. 76-80
-
-
Paccola, L.1
Costa, R.A.2
Folgosa, M.S.3
-
25
-
-
34250774079
-
Beva-cizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes
-
Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Beva-cizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol. 2007;144:124-126.
-
(2007)
Am J Ophthalmol
, vol.144
, pp. 124-126
-
-
Yanyali, A.1
Aytug, B.2
Horozoglu, F.3
Nohutcu, A.F.4
-
26
-
-
34748876124
-
A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema
-
Diabetic Retinopathy Clinical Research Network
-
Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114;1860-1867.
-
(2007)
Ophthalmology
, vol.114
, pp. 1860-1867
-
-
-
27
-
-
0034765032
-
Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema
-
Fine HF, Baffi J, Reed GF, et al. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol. 2001;132:794-796.
-
(2001)
Am J Ophthalmol
, vol.132
, pp. 794-796
-
-
Fine, H.F.1
Baffi, J.2
Reed, G.F.3
-
28
-
-
34250199569
-
Intravitreal beva-cizumab for treatment of uveitic macular edema
-
Coma MC, Sobrin L, Onal S, et al. Intravitreal beva-cizumab for treatment of uveitic macular edema. Ophthalmology. 2007;114:1574-1579.
-
(2007)
Ophthalmology
, vol.114
, pp. 1574-1579
-
-
Coma, M.C.1
Sobrin, L.2
Onal, S.3
-
29
-
-
38049123471
-
Intravitreal beva-cizumab (Avastin) as a treatment for refractory macular edema in patients with uveitis: A pilot study
-
Mackensen F, Heinz C, Becker M, et al. Intravitreal beva-cizumab (Avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina. 2008;28:41-45.
-
(2008)
Retina
, vol.28
, pp. 41-45
-
-
Mackensen, F.1
Heinz, C.2
Becker, M.3
-
30
-
-
0036970074
-
Correlation of increased vascular endothelial growth factor with neovasculariza-tion and permeability in ischemic central retinal vein occlusion
-
Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovasculariza-tion and permeability in ischemic central retinal vein occlusion. Arch Ophthalmol. 2002;120:1644-1650.
-
(2002)
Arch Ophthalmol
, vol.120
, pp. 1644-1650
-
-
Boyd, S.R.1
Zachary, I.2
Chakravarthy, U.3
-
31
-
-
37349107798
-
Intravitreal be-vacizumab injections for treatment of central retinal vein occlusion: Six-month results of a prospective trial
-
Priglinger SG, Wolf AH, Kreutzer TC, et al. Intravitreal be-vacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina. 2007;27:1004-1012.
-
(2007)
Retina
, vol.27
, pp. 1004-1012
-
-
Priglinger, S.G.1
Wolf, A.H.2
Kreutzer, T.C.3
-
32
-
-
36248981014
-
Early bevacizumab treatment of central retinal vein occlusion
-
Ferrara DC, Koizumi H, Spaide RF, et al. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol. 2007;144:864-871.
-
(2007)
Am J Ophthalmol
, vol.144
, pp. 864-871
-
-
Ferrara, D.C.1
Koizumi, H.2
Spaide, R.F.3
-
33
-
-
37349040676
-
Intravitreal bevacizumab (Avastin) in central retinal vein occlusion
-
Hsu J, Kaiser RS, Sivalingam A, et al. Intravitreal bevacizumab (Avastin) in central retinal vein occlusion. Retina. 2007;27:1013-1019.
-
(2007)
Retina
, vol.27
, pp. 1013-1019
-
-
Hsu, J.1
Kaiser, R.S.2
Sivalingam, A.3
-
34
-
-
23744502535
-
Pathogenesisofmacular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6
-
NomaH,FunatsuH,YamasakiM,etal.Pathogenesisofmacular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005;140:256-261.
-
(2005)
Am J Ophthalmol
, vol.140
, pp. 256-261
-
-
Noma, H.1
Funatsu, H.2
Yamasaki, M.3
-
35
-
-
34247231034
-
Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion
-
Rabena MD, Pieramici DJ, Castellarin AA, et al. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007;27:419-425.
-
(2007)
Retina
, vol.27
, pp. 419-425
-
-
Rabena, M.D.1
Pieramici, D.J.2
Castellarin, A.A.3
-
36
-
-
40549120630
-
Intravitreal bevacizumab for the treatmentof macular oedema secondary to branch retinal vein occlusion
-
Kreutzer TC, Alge CS, Wolf AH, et al. Intravitreal bevacizumab for the treatmentof macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2008;92:351-355.
-
(2008)
Br J Ophthalmol
, vol.92
, pp. 351-355
-
-
Kreutzer, T.C.1
Alge, C.S.2
Wolf, A.H.3
-
37
-
-
34250343012
-
Anti-vascular endothelial growth factor be-vacizumab (avastin) for radiation retinopathy
-
Finger PT, Chin K. Anti-vascular endothelial growth factor be-vacizumab (avastin) for radiation retinopathy. Arch Ophthalmol. 2007;125:751-756.
-
(2007)
Arch Ophthalmol
, vol.125
, pp. 751-756
-
-
Finger, P.T.1
Chin, K.2
-
38
-
-
34748830341
-
Intravitreal be-vacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma
-
Mason JO III, Albert MA Jr, Persaud, TO, et al. Intravitreal be-vacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma. Retina. 2007;27:903-907.
-
(2007)
Retina
, vol.27
, pp. 903-907
-
-
Mason III, J.O.1
Albert Jr, M.A.2
Persaud, T.O.3
-
39
-
-
36448946551
-
Primary intravit-real bevacizumab for the management of pseudophakic cystoid macular edema: Pilot study of the Pan-American Collaborative Retina Study Group
-
Arevalo JF, Garcia-Amaris RA, Roca JA, et al. Primary intravit-real bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group. J Cataract Refract Surg. 2007;33:2098-2105.
-
(2007)
J Cataract Refract Surg
, vol.33
, pp. 2098-2105
-
-
Arevalo, J.F.1
Garcia-Amaris, R.A.2
Roca, J.A.3
-
40
-
-
37349096559
-
Efficacy of in-travitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema
-
Spitzer MS, Ziemssen F, Yoeruek E, et al. Efficacy of in-travitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. J Cataract Refract Surg. 2008;34:70-75.
-
(2008)
J Cataract Refract Surg
, vol.34
, pp. 70-75
-
-
Spitzer, M.S.1
Ziemssen, F.2
Yoeruek, E.3
-
41
-
-
34548205365
-
Findings in fluorescein angiography and optical coherence tomography after intravit-real bevacizumab in type 2 idiopathic macular telangiectasia
-
Issa PC, Holz FG, Scholl HPN, et al. Findings in fluorescein angiography and optical coherence tomography after intravit-real bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology. 2007;114:1736-1742.
-
(2007)
Ophthalmology
, vol.114
, pp. 1736-1742
-
-
Issa, P.C.1
Holz, F.G.2
Scholl, H.P.N.3
-
42
-
-
34250782794
-
Intravitreal beva-cizumab (Avastin) injection in ocular ischemic syndrome
-
Amselem L, Montero J, Diaz-Llopis M, et al. Intravitreal beva-cizumab (Avastin) injection in ocular ischemic syndrome. Am J Ophthalmol. 2007;144:122-124.
-
(2007)
Am J Ophthalmol
, vol.144
, pp. 122-124
-
-
Amselem, L.1
Montero, J.2
Diaz-Llopis, M.3
-
43
-
-
34548032578
-
Intravitreal injection of beva-cizumab for cystoid macular edema in retinitis pigmentosa
-
Melo GB, Farah ME, Aggio FB. Intravitreal injection of beva-cizumab for cystoid macular edema in retinitis pigmentosa. Acta Ophthalmol Scand. 2007;85:461-463.
-
(2007)
Acta Ophthalmol Scand
, vol.85
, pp. 461-463
-
-
Melo, G.B.1
Farah, M.E.2
Aggio, F.B.3
|